| New Direction Counseling Center, Llc | |
|
1200 N West Ave Ste 809 Jackson MI 49202-2196 | |
| (517) 257-7846 | |
| Not Available |
| Full Name | New Direction Counseling Center, Llc |
|---|---|
| Speciality | Counselor |
| Location | 1200 N West Ave Ste 809, Jackson, Michigan |
| Authorized Official Name and Position | Laura Maes (LICENSED PROFESSIONAL COUNSELOR) |
| Authorized Official Contact | 5179980999 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| New Direction Counseling Center, Llc 1200 N West Ave Ste 809 Jackson MI 49202-2196 Ph: (517) 998-0999 | New Direction Counseling Center, Llc 1200 N West Ave Ste 809 Jackson MI 49202-2196 Ph: (517) 257-7846 |
| NPI Number | 1114496387 |
|---|---|
| Provider Enumeration Date | 11/17/2018 |
| Last Update Date | 04/24/2019 |
| Medicare PECOS PAC ID | 1658708516 |
|---|---|
| Medicare Enrollment ID | O20200305001862 |
News Archive
Australian drug development company Bionomics Limited will launch a key Phase 2 trial of its novel anxiety drug BNC210 as a treatment for post-traumatic stress disorder (PTSD), following a US$12 million private placement to US institutional investors.
Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP Venture Partners in the financing is a syndicate of corporate investors, including Astellas Venture Management, Genzyme Ventures and a third undisclosed corporate investor.
Results from a double-blind, placebo-controlled study of silymarin, which is derived from the milk thistle plant, have shown that this herbal remedy may be a useful treatment option for non-alcoholic steatohepatitis (NASH).
In connection with the New York Times' recent coverage of hormone therapy1, Pfizer Inc. today released important facts and context to respond to the newspaper's account. Pfizer believes the coverage is based on a misleading and selective reading of both the science and history of hormone therapy (HT) medicines.
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114496387 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YP2500X | Counselor - Professional | (* (Not Available)) | Primary |
| Provider Name | Raymond J Webb |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1639593742 PECOS PAC ID: 0941266068 Enrollment ID: I20041209000472 |
News Archive
Australian drug development company Bionomics Limited will launch a key Phase 2 trial of its novel anxiety drug BNC210 as a treatment for post-traumatic stress disorder (PTSD), following a US$12 million private placement to US institutional investors.
Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP Venture Partners in the financing is a syndicate of corporate investors, including Astellas Venture Management, Genzyme Ventures and a third undisclosed corporate investor.
Results from a double-blind, placebo-controlled study of silymarin, which is derived from the milk thistle plant, have shown that this herbal remedy may be a useful treatment option for non-alcoholic steatohepatitis (NASH).
In connection with the New York Times' recent coverage of hormone therapy1, Pfizer Inc. today released important facts and context to respond to the newspaper's account. Pfizer believes the coverage is based on a misleading and selective reading of both the science and history of hormone therapy (HT) medicines.
› Verified 4 days ago
| Provider Name | Donna J Richardson |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1952725137 PECOS PAC ID: 2365870714 Enrollment ID: I20200317002224 |
News Archive
Australian drug development company Bionomics Limited will launch a key Phase 2 trial of its novel anxiety drug BNC210 as a treatment for post-traumatic stress disorder (PTSD), following a US$12 million private placement to US institutional investors.
Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP Venture Partners in the financing is a syndicate of corporate investors, including Astellas Venture Management, Genzyme Ventures and a third undisclosed corporate investor.
Results from a double-blind, placebo-controlled study of silymarin, which is derived from the milk thistle plant, have shown that this herbal remedy may be a useful treatment option for non-alcoholic steatohepatitis (NASH).
In connection with the New York Times' recent coverage of hormone therapy1, Pfizer Inc. today released important facts and context to respond to the newspaper's account. Pfizer believes the coverage is based on a misleading and selective reading of both the science and history of hormone therapy (HT) medicines.
› Verified 4 days ago
News Archive
Australian drug development company Bionomics Limited will launch a key Phase 2 trial of its novel anxiety drug BNC210 as a treatment for post-traumatic stress disorder (PTSD), following a US$12 million private placement to US institutional investors.
Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP Venture Partners in the financing is a syndicate of corporate investors, including Astellas Venture Management, Genzyme Ventures and a third undisclosed corporate investor.
Results from a double-blind, placebo-controlled study of silymarin, which is derived from the milk thistle plant, have shown that this herbal remedy may be a useful treatment option for non-alcoholic steatohepatitis (NASH).
In connection with the New York Times' recent coverage of hormone therapy1, Pfizer Inc. today released important facts and context to respond to the newspaper's account. Pfizer believes the coverage is based on a misleading and selective reading of both the science and history of hormone therapy (HT) medicines.
› Verified 4 days ago
Alexis Ahlbaum Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 5633 Poplar Dr, Jackson, MI 49201 Phone: 517-270-1994 | |
Cycle Of Life Support Chs Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1520 E Ganson St, Jackson, MI 49202 Phone: 616-275-8930 Fax: 616-608-3693 | |
Inner Guidance Counseling Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 608 W Michigan Ave, Jackson, MI 49201 Phone: 517-416-8878 Fax: 517-962-5316 | |
Center For Family Health Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 505 N Jackson St, Jackson, MI 49201 Phone: 517-748-5500 | |
Lifeways Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1200 N. West Avenue, Jackson, MI 49202 Phone: 517-780-3332 Fax: 517-796-4532 | |
Highfields Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1206 Clinton Rd, Jackson, MI 49202 Phone: 517-783-4250 | |
Lifeways Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 1200 N. West Avenue, Jackson, MI 49202 Phone: 517-789-1200 Fax: 517-789-1276 |